![]() Intellia Therapeutics Intellia is developing therapeutic products to help people with genetic diseases. | ![]() Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases. | ![]() Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics. | ||
Founding Date | Founding Date 2014 | Founding Date 2010 | Founding Date 1992 | Founding Date 1980 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Cambridge, US HQ | Locations Novato, US HQ | Locations Cambridge, US HQ Boulogne Billancourt, FR Berlin, DE Dublin, IE Milano, IT Chiyoda City, JP see more | |
Employees | Employees 27028% increase | Employees 74021% increase | Employees 1,2134% increase | Employees 74349% increase |
Valuation ($) | Valuation ($) 3.6 b | Valuation ($) 3.5 b | Valuation ($) 250.3 m | Valuation ($) 5.7 b |
Twitter followers | Twitter followers 9.3 k | Twitter followers N/A | Twitter followers 9.9 k | Twitter followers 4.1 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 7 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 8 | Number of tweets (last 30 days) 25 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 23.3 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 4.8 | Average likes per tweet (last 30 days) 8.5 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 100% |
Alexa Website Rank | Alexa Website Rank 199835 | Alexa Website Rank N/A | Alexa Website Rank 374950 | Alexa Website Rank 522950 |
Employee Rating | Employee Rating 3.9 | Employee Rating 4.5 | Employee Rating 3.6 | Employee Rating 3.9 |
Financial | ||||
Revenue (est.) | Revenue (est.) $58m (FY, 2020) | Revenue (est.) $271m (FY, 2020) | Revenue (est.) $250.7m (FY, 2020) | Revenue (est.) $540.1m (FY, 2020) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $5.4m (FY, 2020) | Cost of goods N/A |
Gross profit | Gross profit $58m (FY, 2020) | Gross profit N/A | Gross profit $245.3m (FY, 2020) | Gross profit N/A |
Net income | Net income ($134.2m) (FY, 2020) | Net income ($186.6m) (FY, 2020) | Net income ($618.7m) (FY, 2020) | Net income ($554.1m) (FY, 2020) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 200.1m | Total funding raised $ 409m | Total funding raised N/A |
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
View companyBluebird Bio is a developer of gene therapies for severe genetic diseases and cancer.
View companySarepta Therapeutics is a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics.
View company